| Completed | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Phase 3 | 2018-08-16 |
| Completed | Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnos Newly Diagnosed FLT3 Mutated AML | Phase 3 | 2018-08-15 |
| Withdrawn | A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Muta Relapsed/Refractory FLT3-mutated AML | Phase 2 | 2018-01-01 |
| Completed | Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma Esophagogastric Adenocarcinoma | Phase 1 | 2017-04-14 |
| Unknown | Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST GIST With D842V Mutated PDGFRA Gene | Phase 3 | 2016-08-01 |
| Completed | Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification Recurrent/Refractory Glioblastoma | Phase 2 | 2016-04-01 |
| Completed | Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | 2016-02-01 |
| Completed | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2015-09-01 |
| Completed | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 2 | 2015-09-01 |
| Completed | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloi Newly Diagnosed AML With FLT3 Activating Mutations | Phase 2 | 2015-01-01 |
| Completed | A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mut Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies | Phase 2 | 2012-10-01 |
| Completed | Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | Phase 2 | 2012-07-01 |
| Terminated | Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas Glioma | Phase 2 | 2011-04-01 |
| Completed | Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Delet D842-related Mutant GIST | Phase 2 | 2011-04-01 |
| Withdrawn | A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetax Carcinoma, Non-Small-Cell Lung | Phase 2 | 2007-05-01 |
| Completed | CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2005-12-01 |
| Available | Individual Patient Compassionate Use of Crenolanib FLT3-ITD Mutation, FLT3/TKD Mutation, PDGFR-Alpha D842V | — | — |